We are thrilled to announce that Isoprotrace®, our Gallium-68 Gozetotide preparation kit for prostate cancer imaging, has received marketing authorization in the United Kingdom. This approval represents a significant milestone in the advancement of diagnostic tools for prostate cancer and highlights our ongoing commitment to improving patient care worldwide. Isoprotrace® provides healthcare providers with an innovative diagnostic option for the detection and imaging of prostate cancer, offering a critical tool in the fight against this disease. In partnership with Light Medical, our trusted distributor in the United Kingdom, we will work to make Isoprotrace® readily available to medical facilities across the country. “We are incredibly proud to reach this important milestone and are grateful to our dedicated team, partners, and supporters who helped make this achievement possible,” said Tzachi Levy, General Manager of Isotopia’s aseptic plant. “This approval marks a major step forward in providing healthcare providers with the tools they need to make a difference in the lives of patients worldwide.” “We are proud to partner with Isotopia in bringing Isoprotrace® to the United Kingdom. This approval is a major milestone in the fight against prostate cancer, and we look forward to making this innovative diagnostic tool widely available to healthcare providers across the country. Together, we are committed to improving patient care and supporting advancements in prostate cancer diagnostics,” said William Bryan, Director, Light Medical. Isoprotrace® has already been approved in the Netherlands, Germany, and Denmark and is expected to be available soon in over 10 EU countries. With a robust and reliable supply chain and a proven compliance record, Isotopia is committed to expanding patient access to this innovative product, while enhancing diagnostic accuracy and improving treatment outcomes for prostate cancer. About Isoprotrace®: Isoprotrace® is a PSMA-11 (also known as Gozetotide) radiolabelling kit specifically designed for prostate cancer imaging. This ready-to-use, multi-dose kit allows for the efficient preparation of Gallium (68Ga) Gozetotide solution for I.V. injection. For detailed indications, please refer to the product’s SmPC.